Table 3.
Recent examples of micelle-based drug delivery systems for breast cancer therapy.
| Vesicular System | Drug/s/API/s | Pathway/Receptor/ Targeting Moiety/ Overexpressed Factors/ Mode of Action |
Progress | Reference |
|---|---|---|---|---|
| Drug loaded micelle | PTX | F3 targeting peptide/nucleolin overexpression | in vitro and in vivo |
[120] |
| Lipoprotein based micelle | Tetra-O-methyl nordihydroguaiaretic acid (M4N) | LDL receptor, Apolipoprotein B targeting moiety | in vitro and in vivo |
[121] |
| Drug loaded micelle | DTX, Coumarin, Taxotere® | Heparin targeting complex and pH based drug delivery system | in vitro and in vivo |
[122] |
| Polymeric prodrug micelle | DOX -P 123 (prodrugs group) | Phenylboric acid-modified F127 tumor-targeting copolymer | in vitro and in vivo |
[123] |
| Drug loaded micelle | Zileuton™ | ALOX5 pathway inhibitor of cancer stem cells | in vitro and in vivo |
[124] |
| Stimuli-responsive nano polymeric micelle | PTX | Stimuli-responsive nano polymeric micelle targeting complex | in vitro and ex vivo |
[125] |
| Drug based polymeric micelle | DOX | CD44 and CD24 receptors/ polymeric targeting complex | in vitro and in vivo |
[126] |